Dalbonova 500, Dalbavancin, Antibiotics & Infections, Online Pharmacy, ZarvyPharm
Home About us Blog
ANTIBIOTICS Skin/Soft Tissue Infection Systemic Infection MRSA Infection

Dalbonova 500, Solution For Injection

★★★★★
★★★★★
0

(0)

Generic For DALVANCE
Active Ingredient DALBAVANCIN
Strength 500MG
Manufacturer BDR PHARMA
Dalbonova 500 injection box, front view with label visible
Dalbonova 500 injection box, angled view with packaging visible
Dalbonova 500 injection box, front view with label visible
Dalbonova 500 injection box, angled view with packaging visible
Best available coupon applied for preview!
Use code ZARVY26 at checkout to get 15% OFF your order.
COUPON CODE
ZARVY26
15% OFF
Pack Size Price Per Unit Unit Price QTY CART Best Coupon Price
MAX DISCOUNT
3 BOXES - 3 VIALS $ 147.33 $ 442.00
$ 375.70
Apply ZARVY26 (-15%)
You save $ 66.30
6 BOXES - 6 VIALS $ 138.67
6% $ 884.00
$ 832.00
$ 707.20
Apply ZARVY26 (-15%)
You save $ 124.80
★ Best Value 12 BOXES - 12 VIALS $ 129.33
12% $ 1,768.00
$ 1,552.00
$ 1,319.20
Apply ZARVY26 (-15%)
You save $ 232.80
See your savings before you checkout!
With code ZARVY26, get the lowest price on every option above.
Coupon
ZARVY26
Discount
15% OFF
Max Savings
$ 232.80 on 12 Boxes
Go to Cart →
🔒 Secure Checkout

Exchange & Returns Information

 

 

Reference

Reference information will be available soon.

Product Description

Dalbonova 500, Solution for Injection contains dalbavancin, a semisynthetic lipoglycopeptide antibiotic with potent activity against a wide range of Gram-positive pathogens. It exerts bactericidal activity by inhibiting bacterial cell-wall synthesis through high-affinity binding to the D-alanyl-D-alanine terminus of cell-wall precursors, thereby preventing peptidoglycan cross-linking.

Its notably prolonged half-life (approximately 14 days) permits single- or two-dose IV regimens, which can improve patient compliance and enable outpatient parenteral antimicrobial therapy (OPAT). Dalbavancin is especially valuable in managing methicillin-resistant Staphylococcus aureus (MRSA) and complicated skin and soft tissue infections (SSTIs), particularly for patients with limited IV access or those who require infrequent dosing.

For other infection types or broader pathogen coverage, clinicians may consider alternative agents such as Zithromax (azithromycin), Vibramycin (doxycycline), or Novamox (amoxicillin) depending on the organism and clinical scenario. Dalbonova 500 may be reliably sourced through an online pharmacy such as ZarvyPharm, ensuring global accessibility where permitted.

Indications & Uses

  • Dalbonova 500 (dalbavancin) is indicated for complicated Gram-positive skin and soft tissue infections and selected systemic Gram-positive infections where prolonged IV coverage or outpatient parenteral antimicrobial therapy (OPAT) is appropriate.
  • Complicated SSTIs caused by susceptible Gram-positive organisms, including MRSA, MSSA, and streptococcal species.
  • Management of MRSA infections in both hospital and community settings; suitable for acute treatment and selective suppressive strategies in chronic/relapsing cases.
  • Selected systemic infections (e.g., bloodstream infections, infective endocarditis, osteomyelitis) when long-acting Gram-positive coverage and OPAT are clinically justified.
  • When Gram-negative coverage or different spectrum is required, consider alternative or adjunct agents such as Zithromax (azithromycin), Vibramycin (doxycycline), or Novamox (amoxicillin) based on organism susceptibility.
  • This product may be obtained through an online pharmacy such as ZarvyPharm, where local regulations permit.

Benefits & Effectiveness

  • Potent bactericidal activity against Gram-positive bacteria including resistant strains such as MRSA and vancomycin-susceptible Enterococcus faecalis.
  • Extremely long half-life supports single or infrequent dosing, reducing hospital stay and improving adherence.
  • Demonstrated efficacy in difficult-to-treat skin infections, including those with abscesses, cellulitis, or surgical wound complications.
  • Favorable safety profile with low nephrotoxicity and minimal drug-drug interactions, making it a reliable option compared to alternative agents such as Zithromax (azithromycin), Vibramycin (doxycycline), or Novamox (amoxicillin).

Directions for Use

Follow manufacturer storage and stability guidance for vials and reconstituted solutions.

  • Store unopened vials at controlled room temperature below 25°C and protect from light.
  • Reconstituted or diluted solutions should be used promptly or stored only under manufacturer-recommended stability conditions; do not freeze.
  • Keep in original packaging until use and out of reach of children.

Storage

  • Administer Dalbonova 500 as an intravenous infusion under clinical supervision; follow manufacturer instructions for preparation and dilution.
  • Formulation: IV infusion only. Not for IM or SC administration.
  • Adult dosing options: single 1500 mg IV infusion over ~30 minutes OR two-dose regimen of 1000 mg IV on day 1 followed by 500 mg IV on day 8. Do not exceed recommended intervals.
  • Pediatric (weight-based, examples): birth to <6 years ~22.5 mg/kg IV single infusion (max 1500 mg); 6 to <18 years ~18 mg/kg IV single infusion (max 1500 mg). Confirm dosing with a pediatric specialist and local labeling.
  • Administration notes: prepare/dilute per manufacturer guidance, use aseptic technique, infuse at recommended rate, monitor for infusion-related reactions and hypersensitivity during and after infusion.
  • Hepatic impairment: dose adjustment may be required in severe hepatic impairment—consult full prescribing information.

Possible Side Effects

Be aware of common, moderate, and rare but serious adverse reactions; monitor patients and discontinue Dalbonova 500 (dalbavancin) if severe events occur.

  • Common: nausea, diarrhea, headache, flushing, injection-site or infusion-related reactions.
  • Moderate: elevated liver enzymes, pruritus, mild rash.
  • Serious (rare): anaphylaxis or severe hypersensitivity reactions; Clostridioides difficile–associated diarrhea. Discontinue therapy and seek immediate medical care for severe reactions.
  • Monitoring: assess liver function tests and observe for signs of hypersensitivity or severe gastrointestinal events during and after treatment.

FAQs

Its prolonged half-life allows for single or two-dose regimens, minimizing the need for prolonged hospitalization and daily IV access.
Yes, in patients with severe renal impairment (CrCl <30 mL/min) not receiving hemodialysis.
No, its activity is limited to vancomycin-susceptible strains.
Symptomatic relief and reduction in lesion size are often observed within 48–72 hours, with continued improvement over the treatment course.
Yes, pediatric dosing regimens are available and effective for the same Gram-positive spectrum as adults.

Ratings & Reviews

Reviewed by 0 Users

0/5
★★★★★
★★★★★
5★
0%
4★
0%
3★
0%
2★
0%
1★
0%

Write a Review:

✓ The 'Write a Review' button appears only when an order includes this product and the product item in that order is marked as 'Delivered'.

✓ Clicking the button will redirect you to 'My Account > Orders > Orders Processing', where you can leave a review for a delivered item.

💡 Each product item can be reviewed only once, after it has been marked as 'Delivered'.


Multiple orders:

✓ If you bought this product more than once on different days, you can write a separate review for each order.

💡 When Order A is marked 'Delivered', the button takes you to Order A's details page.

Later, when Order B is also marked Delivered, the button stays active and takes you to Order B's details page for another review.

No reviews yet. Be the first to review this product!

Alternatives

Combo Deals

No combo deals available at the moment.